Botanix wins additional US patent allowance for Sofdra

Botanix Pharmaceuticals said the US Patent and Trademark Office has granted a Notice of Allowance for a new patent tied to Sofdra’s drug substance, extending potential protection in the US to May 2040. The move could strengthen the company’s market exclusivity around its FDA-approved hyperhidrosis treatment and support future licensing or partnership value.

Why it matters: - The new patent could make Sofdra harder to copy in the U.S. market. - The allowed claims are expected to extend protection against unauthorized commercial manufacturing of the drug substance into May 2040. - Longer exclusivity can support revenue durability and improve the asset’s appeal for licensing or partnership discussions.

What happened: - Botanix Pharmaceuticals said the U.S. Patent and Trademark Office issued a Notice of Allowance for patent application Serial No. 17/611,158. - The application is titled “Crystalline Form of Sofpironium Bromide and Preparation Method Thereof.” - The application covers intellectual property tied to the drug substance that underpins Sofdra, Botanix’s FDA-approved treatment for primary axillary hyperhidrosis in adults and pediatric patients aged nine and older. - The company announced the allowance on July 12, 2026.

The details: - The allowed claims cover proprietary aspects of the sofpironium drug substance technology used in Sofdra’s commercial manufacture. - Once the patent issues, Botanix expects it to strengthen U.S. intellectual property protection around Sofdra. - The patent protection is expected to run to May 2040 for the drug substance. - Botanix described the crystalline form of sofpironium bromide as the actual chemical entity and the hardest type of patent to design around. - Chief Executive Officer Howie McKibbon said strengthening the company’s intellectual property estate around Sofdra remains a strategic priority. - McKibbon said the Notice of Allowance expands Botanix’s U.S. patent portfolio and supports the long-term commercial opportunity for Sofdra out to 2040. - Botanix said multiple issued patents protecting Sofdra to 2040 give the company a long window of market exclusivity.

Between the lines: - The allowance broadens Botanix’s patent moat around a lead commercial product, which matters most for a dermatology asset with ongoing U.S. sales potential. - A stronger patent position can reduce investor concern about competition, while also making the product more useful in deal talks. - Botanix framed the filing as part of a broader effort to build out its U.S. dermatology offering.

What's next: - The patent must still issue before the protection is in place. - Botanix said it will continue protecting the innovations behind Sofdra as it expands its U.S. dermatology business. - The company’s U.S. patent portfolio around Sofdra now appears positioned to remain a key commercial asset through 2040.

The bottom line: - Botanix added another layer of protection around Sofdra, and the timing suggests the company is working to lock in a longer U.S. exclusivity runway for its lead product.